Sulperazon’s revenue trends
In 2Q17, Pfizer’s (PFE) Sulperazon generated revenues of around $110 million, which reflected ~5% growth on a year-over-year (or YoY) basis and a 10% decline on a quarter-over-quarter basis. In 1H17, Sulperazon reported revenues of ~$232 million for 15% growth on a YoY basis.
Sulperazon is used for the treatment of respiratory tract infections, urinary tract infections, cholecystitis, cholangitis, septicemia, meningitis, infections of the genital tract, and various other bacterial infections. The chart below illustrates the revenue curve of Pfizer’s Sterile Injection Pharmaceuticals segment from 2Q16 to 2Q17.
Medrol’s revenue trends
In 2Q17, Medrol generated revenues of ~$123 million, which represents ~7% growth on a YoY basis and 2% growth on a quarter-over-quarter basis. In 1H17, Medrol generated revenues of ~$243 million, which reflects 7% growth on a YoY basis.
Medrol is used for the treatment of arthritis, severe allergic reactions, dermatologic diseases, ulcerative colitis, multiple sclerosis, and respiratory disorders.
Tygacil’s revenue trends
In 2Q17, Tygacil generated revenues of ~$57 million, which represents an ~3% decline on a YoY basis and a 23% decline on a quarter-over-quarter basis. In 1H17, Tygacil generated revenues of ~$131 million, reflecting a 2% decline on a YoY basis.
Tygacil (tigecycline) is a tetracycline antibacterial drug used for the treatment of skin infections, intra-abdominal infections, and community-acquired bacterial pneumonia.
Fragmin and Precedex
In 2Q17, Fragmin reported revenues of ~$71 million, representing a 13% decline on a YoY basis. Fragmin is used for the prevention of ischemic complications in unstable angina and non-Q-wave myocardial infarction.
In 2Q17, Precedex generated revenues of ~$67 million compared to $66 million in 2Q16. In 1H17, Precedex reported revenues of ~$132 million, which reflected ~2% growth YoY. Precedex (dexmedetomidine hydrochloride) is used for the sedation of initially intubated and mechanically ventilated individuals during treatment in an intensive care unit.
Pfizer’s competitors in the sterile injection pharmaceuticals market include Mylan (MYL), Sanofi (SNY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Teva Pharmaceuticals, and AstraZeneca. The iShares US Pharmaceuticals ETF (IHE) invests ~8.5% of its total portfolio in Pfizer.